News About: Pharm. Industry
In regards to obstacle for the global expansion, the only solution is to modify the price policy
“A prerequisite for globalization in the pharmaceutical industry is rapid settlement of predictable and stable price policy at the level of new drug research and development.”
The Korea Pharmaceutical Manufacturers A...
The chief director of the Healthcare division in Bayer Korea will be replaced… Director Roh resigned
It is observed that the head of a pharmaceutical division in Bayer Korea will be replaced.
According to the pharmaceutical industry on the 28th, Sang-kyung Roh, chief director of the Healthcare division since Novembe...
Kunwha Pharmaceutical, The stock price drops to the lowest limit due to recapitalization to raise funds to take over Dream Pharma
Kunwha Pharmaceutical posted a notice of KRW 134.345 billion worth of recapitalization to raise funds to take over 100% shares of the drug manufacturing corporation divided from Dream Pharma.
The number of the newly ...
‘Rushes’ of domestic pharmaceutical companies into clinical studies for global new drugs
As domestic pharmaceutical companies have enlarged the possibility of overseas expansion through their self-developed new drugs, it was noticed that the new drugs has passed clinical trials in the U.S. market, the big...
“A new obesity drug will be used in Korea”
The expectation of the medical industry towards new obesity drugs are growing.
Discussions about ‘The Future Direction of Obesity Medication’ was made at the 41st Autumn Academic Conference in 2014 held by the Korean...
Caught between ‘rebate’ and ‘ethical management’… the suggested solution is a CEO’s will
As controversy, such as the K hospital, about the rebate system in the pharmaceutical industry has recently risen again, it was noticed that a meaningful time and place for the spread of ethical management was arrange...
A series of pharmaceutical companies’ lawsuits… Is it considered as an improper group action?
Recently, domestic pharmaceutical companies in Korea are fearlessly(?) facing lawsuits against the government regarding insurance expenses. They tried to resist against the Ministry of Health and Welfare’s ‘drug price...
Pfizer has the most products in the list of the top 30 outpatient prescriptions
The pharmaceutical company with the most sales product in the collective outpatient prescription market on the third quarter of the year was, of course, Pfizer.
The current circumstance in the pharmaceutical industry...
Generics of Albis, which are more expensive than the original… competing with 10 different products
It is expected that generics of the antiulcer drug ‘Albis’ will be launched in earnest on this November. About 10 products will receive their price and be opened in the market next month.
Albis is a drug that recorde...
KRW 50 billion worth of the Nexium market… having conflicts with improved new generics
The Nexium (Esomeprazole) Market reaching collective KRW 35 billion for the third quarter of the year is like the calm before the storm.
Despite the aggressive sales marketing of improved new drugs, Nexium, the origi...
